首页> 外文期刊>Journal of Medicinal Chemistry >Optimization of an Imidazopyridazine Series of Inhibitors of Plasmodium falciparum Calcium-Dependent Protein Kinase 1 (Pf CDPK1)
【24h】

Optimization of an Imidazopyridazine Series of Inhibitors of Plasmodium falciparum Calcium-Dependent Protein Kinase 1 (Pf CDPK1)

机译:咪唑并恶嗪系列恶性疟原虫钙依赖性蛋白激酶1(Pf CDPK1)抑制剂的优化。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

A structure-guided design approach using a homology model of Plasmodium falciparum calcium-dependent protein kinase 1 (Pf CDPK1) was used to improve the potency of a series of imidazopyridazine inhibitors as potential antimalarial agents. This resulted in high affinity compounds with Pf CDPK1 enzyme IC_(50) values less than 10 nM and in vitro P. falciparum antiparasite EC50 values down to 12 nM, although these compounds did not have suitable ADME properties to show in vivo efficacy in a mouse model. Structural modifications designed to address the ADME issues, in particular permeability, were initially accompanied by losses in antiparasite potency, but further optimization allowed a good balance in the compound profile to be achieved. Upon testing in vivo in a murine model of efficacy against malaria, high levels of compound exposure relative to their in vitro activities were achieved, and the modest efficacy that resulted raises questions about the level of effect that is achievable through the targeting of Pf CDPK1.
机译:使用恶性疟原虫钙依赖性蛋白激酶1(Pf CDPK1)的同源性模型的结构指导设计方法被用来提高一系列咪唑并哒嗪抑制剂作为潜在抗疟药的效力。这导致Pf CDPK1酶IC_(50)值小于10 nM,体外恶性疟原虫抗寄生虫EC50值低至12 nM的高亲和力化合物,尽管这些化合物不具有合适的ADME性质以显示其在小鼠体内的功效模型。旨在解决ADME问题(特别是渗透性)的结构修改最初会伴随抗寄生虫效力的下降,但进一步的优化可以实现化合物轮廓的良好平衡。在鼠类抗疟疾功效模型中进行体内测试后,相对于其体外活性而言,化合物的暴露水平较高,所产生的适度功效引发了对通过靶向Pf CDPK1可获得的作用水平的疑问。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号